Trial Profile
Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs OLX 10020 (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 23 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 09 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2021 New trial record